imagine if NEU could manage to just recruit a few more Angelman...

imagine if NEU could manage to just recruit a few more Angelman and Pitt-Hopkins subjects to complete enrolment for those Phase 2 trials… and then imagine if NEU could just recruit the first Prader Willi subject to get that phase 2 trial underway….

Not a great deal of imagination required here.

As previously stated, Pitt Hopkins enrolment closes this month, so just another week to go.

Also, Prader-Willi recruitment has already commenced - 7 weeks ago.

As for Angelman it’s the only Australian-based NNZ-2591 trial (therefore recruiting from a much smaller patient population) and it is also competing for participants with two other larger studies by Biogen/Ionis and Roche/Genentech. Competition for patients slows recruitment.



On the subject of Autism Spectrum Disorder…

A further study of Acadia’s drug, pimavanserin, was due to commence this week. It’s a Phase 2 study to assess the safety, tolerability and effects of pimavanserin on behavioural rigidity and rigid-compulsive behaviour in adolescents and adults with ASD. The study is being sponsored by the New York State Psychiatric Institute. The 30 person study is estimated to complete in December 2025.

Meanwhile, Acadia is continuing with its Phase 2/3 trial of Pimavanserin for the Treatment of Irritability Associated with Autism Spectrum Disorder. The 228 patient trial, which is followed by an extension study, commenced in August last year and is due to complete in June next year. There are currently two FDA approved drugs (both anti-psychotics) approved for irritability associated with ASD.